Page 135 - Read Online

system (CNS) disorders or by the deposition of Financial support and sponsorship
mucopolysaccharides within the nerve and muscle fibers Nil.
in peripheral nervous system conditions. [2,3] The treatment
of CNS involvement in scleromyxedema patients includes Conflicts of interest
steroids, plasmapheresis, intravenous immunogloblin There are no conflicts of interest.
and chemotherapeutic drugs in various combinations. [4]
REFERENCES
Brain imaging in patients with CNS involvement rarely
shows lesions responsible for this condition and in the 1. Cokonis G, Falaska G, Georgakis A, Heymann WR. Scleromyxedema.
rare cases with lesions demonstrated, spontaneous Clin Dermatol 2006;24:493-7.
remission remains unlikely. [2,4] In conclusion, in cases 2. Berger JR, Dobbs MR, Terhune MH, Maragos WF. The neurologic
complications of scleromyxedema. Medicine 2001;80:313-9.
with scleromyxedema that present with neurological 3. Johkura K, Susuki K, Hasegawa O, Kuroiwa Y, Komatsumoto S.
manifestations, we should consider central nervous Encephalopathy in scleromyxedema. Neurology 1999;53:1138-40.
system pathophysiology and evaluate possible bsrain 4. Fleming KE, Virmani D, Sutton E, Langley R, Corbin J, Pasternak S,
Walsh NM. Scleromyxedema and the dermato-neuro syndrome: case
abnormalities with detailed magnetic resonance images report and review of the literature. J Cutan Pathol 2012;39:508-11.
and treat the patient appropriately. 5. Hummers LK. Scleromyxedema. Curr Opin Rheumatol 2014;26:658-62.

126 Neuroimmunol Neuroinflammation | Volume 3 | May 25, 2016